Evidence map›Paper›PMID 34372955›Full record

ArticleEpidemiology and infection2021

SARS-CoV-2 seroprevalence survey among health care providers in a Belgian public multiple-site hospital.

Reinout Naesens, Helena Mertes, Johan Clukers, Sereina Herzog, Christiane Brands, Philippe Vets, Inneke De Laet, Peggy Bruynseels, Pieter De Schouwer, Sanne van der Maas and 3 more

Open access · goldAbstract read
In one paragraph

Article in Epidemiology and infection, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Reinout NaesensDepartment of Medical Microbiology, ZiekenhuisNetwerk Antwerpen, B-2020Antwerpen, Belgium.ORCID 0000-0003-1004-7737
Helena MertesDepartment of Infectious Disease, ZiekenhuisNetwerk Antwerpen, B-2020Antwerpen, Belgium.
Johan ClukersDepartment of Respiratory Medicine, ZiekenhuisNetwerk Antwerpen, B-2020Antwerpen, Belgium.
Sereina HerzogCentre for Health Economics Research and Modelling of Infectious Diseases (CHERMID), Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, B-2610Wilrijk, Belgium.
Christiane BrandsDepartment of Infectious Disease, ZiekenhuisNetwerk Antwerpen, B-2020Antwerpen, Belgium.
Philippe VetsDepartment of Intensive Care and Anesthesiology, ZiekenhuisNetwerk Antwerpen, Antwerpen, Belgium.
Inneke De LaetDepartment of Intensive Care and Anesthesiology, ZiekenhuisNetwerk Antwerpen, Antwerpen, Belgium.
Peggy BruynseelsDepartment of Medical Microbiology, ZiekenhuisNetwerk Antwerpen, B-2020Antwerpen, Belgium.
Pieter De SchouwerDepartment of Medical Microbiology, ZiekenhuisNetwerk Antwerpen, B-2020Antwerpen, Belgium.
Sanne van der MaasHospital and Medical Directory Board, ZiekenhuisNetwerk Antwerpen, B-2020Antwerpen, Belgium.
Katrien BervoetsHospital and Medical Directory Board, ZiekenhuisNetwerk Antwerpen, B-2020Antwerpen, Belgium.
Niel HensCentre for Health Economics Research and Modelling of Infectious Diseases (CHERMID), Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, B-2610Wilrijk, Belgium.ORCID 0000-0003-1881-0637
Pierre Van DammeCentre for Health Economics Research and Modelling of Infectious Diseases (CHERMID), Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, B-2610Wilrijk, Belgium.
Ziekenhuisnetwerk Antwerpen Stuivenberg · BEUniversity of Antwerp · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is lasting for more than 1 year, the exposition risks of health-care providers are still unclear. Available evidence is conflicting. We investigated the prevalence of antibodies against SARS-CoV-2 in the staff of a large public hospital with multiple sites in the Antwerp region of Belgium. Risk factors for infection were identified by means of a questionnaire and human resource data. We performed hospital-wide serology tests in the weeks following the first epidemic wave (16 March to the end of May 2020) and combined the results with the answers from an individual questionnaire. Overall seroprevalence was 7.6%. We found higher seroprevalences in nurses [10.0%; 95% confidence interval (CI) 8.9-11.2] than in physicians 6.4% (95% CI 4.6-8.7), paramedical 6.0% (95% CI 4.3-8.0) and administrative staff (2.9%; 95% CI 1.8-4.5). Staff who indicated contact with a confirmed coronavirus disease 2019 (COVID-19) colleague had a higher seroprevalence (12.0%; 95% CI 10.7-13.4) than staff who did not (4.2%; 95% CI 3.5-5.0). The same findings were present for contacts in the private setting. Working in general COVID-19 wards, but not in emergency departments or intensive care units, was also a significant risk factor. Since our analysis points in the direction of active SARS-CoV-2 transmission within hospitals, we argue for implementing a stringent hospital-wide testing and contact-tracing policy with special attention to the health care workers employed in general COVID-19 departments. Additional studies are needed to establish the transmission dynamics.

Indexed as

AdolescentAdultAgedBelgiumCOVID-19Cross InfectionFemaleHospitalsHumansMaleMedical Staff, HospitalMiddle AgedNursing Staff, HospitalPersonnel, HospitalRisk FactorsSeroepidemiologic Studieshealth care workerprofessional categoryrisk factorSARS-CoV-2seroprevalence

Identifiers

PMID34372955
PMCPMC8365049
OpenAlexW3189419239

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.